Role of Copeptin in Ruling out Acute Coronary Syndrome and Sizing of Infarction
Abdelrahman Mohamed Hamed Elmarakby;
Abstract
ABSTRACT
Background: Acute coronary syndrome (ACS) is a major health care and economic burden in the world and accounts for more than 1 million hospitalizations annually. The mortality due to ACS is substantial nearly half of all deaths are due to coronary heart disease. Approximately 15–20 million patients per year present to the emergency department (ED) with acute chest pain, about two-thirds of these patients will be found not to have ACS, rule-in and rule-out seem to be equally important. Biomarkers preferably troponins complement the clinical assessment and the 12-lead ECG in the diagnosis of patients with suspected ACS but a major drawback its delayed release in blood stream after ACS and the need for serial cardiac enzymes and prolonged monitoring for the final diagnosis or ruling out, The need for faster diagnosis, more accurate prognostic assessment and treatment decisions has led to the investigations of new biomarkers. Such a new biomarker is copeptin which is currently well understood as a quantitative marker of endogenous stress.
Aim and Objectives is to investigate the effectiveness of using copeptin in safely ruling out NSTE-ACS very early after onset of symptoms and to asses if it has a prognostic value on determining the size of infarction or not.
Background: Acute coronary syndrome (ACS) is a major health care and economic burden in the world and accounts for more than 1 million hospitalizations annually. The mortality due to ACS is substantial nearly half of all deaths are due to coronary heart disease. Approximately 15–20 million patients per year present to the emergency department (ED) with acute chest pain, about two-thirds of these patients will be found not to have ACS, rule-in and rule-out seem to be equally important. Biomarkers preferably troponins complement the clinical assessment and the 12-lead ECG in the diagnosis of patients with suspected ACS but a major drawback its delayed release in blood stream after ACS and the need for serial cardiac enzymes and prolonged monitoring for the final diagnosis or ruling out, The need for faster diagnosis, more accurate prognostic assessment and treatment decisions has led to the investigations of new biomarkers. Such a new biomarker is copeptin which is currently well understood as a quantitative marker of endogenous stress.
Aim and Objectives is to investigate the effectiveness of using copeptin in safely ruling out NSTE-ACS very early after onset of symptoms and to asses if it has a prognostic value on determining the size of infarction or not.
Other data
| Title | Role of Copeptin in Ruling out Acute Coronary Syndrome and Sizing of Infarction | Other Titles | دور الكوبيبتين في استبعاد مرضى متلازمة الشريان التاجي الحادة وعلاقته بحجم احتشاء عضلة القلب | Authors | Abdelrahman Mohamed Hamed Elmarakby | Issue Date | 2019 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.